Related Experiment Video
Updated: Aug 3, 2026
09:43
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
[The dynamic study between EBV-DNA with nasopharyngeal carcinoma]
1Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, China. jwz903@sohu.com
Lin Chuang Er Bi Yan Hou Ke Za Zhi = Journal of Clinical Otorhinolaryngology
|January 10, 2006
Summary
Blood plasma Epstein-Barr virus (EBV) DNA levels effectively monitor nasopharyngeal carcinoma (NPC) treatment response. Elevated EBV DNA indicates residual disease, relapse, or metastasis, aiding in diagnosis.
Area of Science:
- Oncology
- Virology
- Molecular Diagnostics
Background:
- Nasopharyngeal carcinoma (NPC) is a significant health concern.
- Accurate monitoring of treatment response in NPC is crucial for patient outcomes.
- Epstein-Barr virus (EBV) plays a key role in NPC pathogenesis.
Purpose of the Study:
- To investigate the correlation between blood plasma Epstein-Barr virus (EBV) DNA levels and treatment response in NPC patients.
- To assess the utility of EBV DNA detection in identifying tumor growth, decline, residual disease, relapse, and metastasis.
Main Methods:
- Blood plasma samples were collected from NPC patients before and after radiotherapy.
- Polymerase chain reaction (PCR) with restriction enzyme technique was employed to quantify EBV DNA levels.
Main Results:
- A high positivity rate (95.9%) for EBV DNA was observed in NPC patients.
- Complete tumor disappearance correlated with negative EBV DNA.
- Positive EBV DNA was significantly associated with residual tumors (62.7%), relapse (91.7%), and metastasis (100%).
Conclusions:
- Blood plasma EBV DNA is a sensitive and reliable biomarker for monitoring NPC treatment.
- EBV DNA detection aids in the early diagnosis of residual disease, relapse, and metastasis in NPC patients.
